Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

GLP-1 (native; Physiology)

MARKETED

native GLP-1

5
graded findings
5
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 4Very low evidence 1

GLP-1 (native; Physiology) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (native; Physiology) MARKETED
Safety signals No change
Low evidence

Acute GLP-1 infusion did not affect reproductive-hormone secretion in healthy men, contradicting rodent findings.

Acute GLP-1 infusion on the male reproductive axis (crossover RCT), J Clin Endocrinol Met... Source
PopulationAcute single-blind randomised placebo-controlled crossover RCT (8-h GLP-1 infusion, healthy men; small acute mechanistic study).
Fundingacademic-UK public (NIHR / MRC / Wellcome Trust / BBSRC / Imperial)
Scope limitssurrogate/exploratory endpoint
Comparatorsplacebo infusion
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (native; Physiology) MARKETED
Energy expenditure and thermogenesis No change
Very low evidence

Rodent EE-defence reframe (Jacobsen Cell Rep 2024): standard ~22C mouse housing is a cold stress inflating energy expenditure, but independent of ambient temperature...

Jacobsen JM, Petersen N, Torz L, et al. GLP-1 and FGF21 prevent the reduction in metaboli... Source
Full findingRodent EE-defence reframe (Jacobsen Cell Rep 2024): standard ~22C mouse housing is a cold stress inflating energy expenditure, but independent of ambient temperature GLP-1 and FGF21 prevented the FALL in metabolic rate caused by weight loss. This reframes the question from EE-elevation to EE-DEFENCE during deficit. It is a rodent, hypothesis-tier finding - NOT retatrutide-direct - and its human translation is indeterminate.
PopulationMice across 22C vs thermoneutral 30C housing, GLP-1/FGF21 (and MC4R/PYY/GDF15) weight-loss models (Cell Rep 2024;43(8):114501)
Fundingindustry - Novo Nordisk (study performed by Novo Nordisk; authors are Novo Nordisk employees, paper funding/affiliation line)
Scope limitsanimal data; human relevance uncertain; thermoneutrality vs 22C housing reframe; not retatrutide-direct
Comparatorsvehicle / weight-loss control; thermoneutral vs 22C housing
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (native; Physiology) MARKETED
heart-rate-chronotropy Not directional
Low evidence

The GLP-1 receptor localises to myocytes of the human (and monkey) sinoatrial node by validated-monoclonal-antibody immunohistochemistry (and to renal/lung arterial...

Pyke C et al., Endocrinology 2014;155(4):1280-90 Source
Full findingThe GLP-1 receptor localises to myocytes of the human (and monkey) sinoatrial node by validated-monoclonal-antibody immunohistochemistry (and to renal/lung arterial smooth muscle); it is NOT found in working cardiomyocytes - giving an anatomical DIRECT substrate for the GLP-1 heart-rate effect at the sinoatrial node.
Populationhuman and monkey cardiac tissue; validated monoclonal-antibody immunohistochemistry localisation study
Fundingindustry - Novo Nordisk (validated monoclonal antibody; sponsor-authored)
Scope limitssingle-centre/referral-enriched; sponsor-authored COI (Novo Nordisk antibody)
Comparatorsn/a
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (native; Physiology) MARKETED
renal Increase
Low evidence

GLP-1 increases natriuresis principally by inhibiting the sodium-hydrogen exchanger isoform 3 (NHE3) in the renal proximal tubule, a candidate mechanism for the...

Skov J, Rev Endocr Metab Disord 2014;15(3):197-207 Source
Full findingGLP-1 increases natriuresis principally by inhibiting the sodium-hydrogen exchanger isoform 3 (NHE3) in the renal proximal tubule, a candidate mechanism for the antihypertensive effect of GLP-1 receptor agonists; GLP-1 regulation of GFR is more complex and may involve atrial natriuretic peptide and the renin-angiotensin system.
PopulationReview-tier mechanism synthesis of GLP-1 renal actions (human-relevant physiology).
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsmechanism review; cannot outweigh primary; renal GLP-1R localises to arterial smooth muscle not tubular epithelium (direct-tubular NHE3 route is candidate not settled)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 (native; Physiology) MARKETED
Insulin and beta-cell function Mixed
Low evidence

GLP-1 augments glucose-stimulated insulin secretion in a glucose-dependent manner (acting already at fasting glucose, more strongly as glucose rises) and suppresses...

Hare KJ et al. (GLP-1 physiology); per corpus L2-006 Source
Full findingGLP-1 augments glucose-stimulated insulin secretion in a glucose-dependent manner (acting already at fasting glucose, more strongly as glucose rises) and suppresses alpha-cell glucagon secretion in hyperglycaemic and euglycaemic states, lowering hepatic glucose output; GLP-1R blockade with exendin(9-39) raises glucagon and produces fasting hyperglycaemia.
PopulationHealthy humans and T2D (physiology)
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsReused from corpus L2-001/L2-003 (PMID:15985560)/L2-006 (PMID:22855730). Direction mixed: insulinotropic (beta, +) and glucagonostatic (alpha, glucagon decrease). Foundational pure-GLP-1R islet physiology underpinning the offset.
Comparatorssaline; exendin(9-39)